Quick Read – NeOnc and Plus Therapeutics operate in the same CNS oncology space as CNS Pharmaceuticals but carry deeper pipelines, real funding, and commercial traction that can deliver near-term catalysts without the cash constraints and binary risk of single-asset plays. – The…
alyst who called NVIDIA in 2010 just named his top 10 stocks and Neonc Technologies wasn’t one of them. Get them here FREE
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move; new entrants face tougher math from here.
The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss of $3.50 million with cash collapsed to about $800,000, and the stock is still off 42.18% over one year and effectively 100% over five years on a split-adjusted basis. The defining catalyst, Berubicin topline data, was already telegraphed for the first half of 2025. This week’s move resolves that catalyst rather than anticipating it.